TRCT
SPRY icon

Tower Research Capital (TRC)’s ARS Pharmaceuticals SPRY Stock Holding History

Tower Research Capital (TRC)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.2K Buy
11,232
+10,183
+971% +$97.6K ﹤0.01% 2266
2025
Q4 		$12.2K Sell
1,049
-6,404
-86% -$62.3K ﹤0.01% 3504
2025
Q3 		$74.9K Buy
7,453
+1,169
+19% +$16.8K ﹤0.01% 2229
2025
Q2 		$110K Buy
6,284
+158
+3% +$2.28K ﹤0.01% 2306
2025
Q1 		$77.1K Sell
6,126
-39,450
-87% -$475K ﹤0.01% 1921
2024
Q4 		$481K Buy
45,576
+41,269
+958% +$578K 0.01% 1089
2024
Q3 		$62.5K Sell
4,307
-3,383
-44% -$40.2K ﹤0.01% 2594
2024
Q2 		$65.4K Buy
7,690
+7,459
+3,229% +$66.2K ﹤0.01% 2885
2024
Q1 		$2.36K Sell
231
-6,834
-97% -$51K ﹤0.01% 5060
2023
Q4 		$38.7K Sell
7,065
-28,581
-80% -$125K ﹤0.01% 3288
2023
Q3 		$135K Buy
35,646
+26,143
+275% +$172K ﹤0.01% 1743
2023
Q2 		$63.7K Sell
9,503
-198
-2% -$1.32K ﹤0.01% 2384
2023
Q1 		$64K Buy
9,701
+1,539
+19% +$11.8K ﹤0.01% 2284
2022
Q4 		$70K Buy
8,162
+1,542
+23% +$10K ﹤0.01% 2110
2022
Q3 		$35K Sell
6,620
-3,939
-37% -$19.4K ﹤0.01% 3475
2022
Q2 		$45K Sell
10,559
-9,244
-47% -$32.2K ﹤0.01% 2993
2022
Q1 		$70K Buy
19,803
+17,009
+609% +$74K ﹤0.01% 2462
2021
Q4 		$19K Sell
2,794
-1,780
-39% -$14.5K ﹤0.01% 3742
2021
Q3 		$46K Buy
4,574
+3,478
+317% +$85.8K ﹤0.01% 3035
2021
Q2 		$34K Buy
1,096
+439
+67% +$14.1K ﹤0.01% 3360
2021
Q1 		$29K Buy
+657
New +$31.1K ﹤0.01% 3589

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tower Research Capital (TRC)'s SPRY Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its ARS Pharmaceuticals (SPRY) stake by 971% in Q1 2026, buying an estimated $97.6K and bringing the position to 11,232 shares worth $90.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

Tower Research Capital (TRC) first reported a position in SPRY in Q1 2021 and has held it in 21 quarters since. The position peaked at $481K in Q4 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Tower Research Capital (TRC) held 11,232 shares of ARS Pharmaceuticals worth $90.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 10,183 ARS Pharmaceuticals shares in Q1 2026, an estimated $97.6K.
  • ARS Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2266 holding.
  • Tower Research Capital (TRC) first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s ARS Pharmaceuticals position peaked at $481K in Q4 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.